[1-(2-pyridinyl)cyclohexyl]methanamine | 204067-08-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: [1-(2-pyridinyl)cyclohexyl]methanamine
• 英文别名: 1-aminomethyl-1-(pyridin-2-yl)cyclohexane；(1-(pyridin-2-yl)cyclohexyl)methanamine；[1-(2-pyridyl)cyclohexyl]methylamine；1-(2-pyridyl) 1-aminomethyl cyclohexane；[1-(pyridin-2-yl)cyclohexyl]methylamine；(1-pyridin-2-ylcyclohexyl)methanamine
• CAS: 204067-08-3
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: XGYWBGLMCUFVOB-UHFFFAOYSA-N

物化性质

• 沸点：
  315.4±15.0 °C(Predicted)
• 密度：
  1.017±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [1-(2-pyridinyl)cyclohexyl]methanamine 在 哌啶 、 盐酸 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 3-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-6-methoxy-N-[(1-pyridin-2-ylcyclohexyl)methyl]-1,2,4,9-tetrahydrocarbazole-3-carboxamide
  参考文献：
  名称：

  Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis

  摘要：

  The design and parallel synthesis of potent, small molecule partial agonists of Neuromedin B receptor based on the 3-amino-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid amide core is described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.045
• 作为产物：
  描述：

  2-吡啶乙腈 在 氨 、 氢气 、 sodium hydride 、 potassium hydroxide 作用下， 以 乙醚 、 乙醇 、 二甲基亚砜 、 mineral oil 为溶剂， 反应 40.0h， 生成 [1-(2-pyridinyl)cyclohexyl]methanamine
  参考文献：
  名称：

  Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2

  摘要：

  N-Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) that play critical roles in inflammatory reactions, and FPR-specific interactions can possibly be used to facilitate the resolution of pathological inflammatory reactions. We here report the synthesis and biological evaluation of six pairs of chiral ureidopropanamido derivatives as potent and selective formyl peptide receptor-2 (FPR2) agonists that were designed starting from our lead agonist (S)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]propanamide ((S)-9a). The new compounds were obtained in overall yields considerably higher than (S)-9a. Several of the new compounds showed agonist properties comparable to that of (S)-9a along with higher selectivity over FPR1. Molecular modeling was used to define chiral recognition by FPR2. In vitro metabolic stability of selected compounds was also assessed to obtain preliminary insight on drug-like properties of this class of compounds. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.007

文献信息

• [EN] FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY<br/>[FR] DÉRIVÉS DE [1,2,4]THIADIAZINE FUSIONNÉS AGISSANT EN TANT QU'INHIBITEURS DE KAT DE LA FAMILLE DES MYST
  申请人：CTXT PTY LTD

  公开号：WO2019043139A1

  公开（公告）日：2019-03-07

  A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

  一种化合物的化学式（I）：抑制MYST家族中一个或多个KATs的活性，即TIP60、KAT6B、MOZ、HBO1和MOF。
• Non-peptide bombesin receptor antagonists
  申请人：Warner-Lambert Company

  公开号：US06194437B1

  公开（公告）日：2001-02-27

  The compounds of the instant invention are novel compounds of Formula I or a pharmaceutically acceptable salt thereof wherein Ar is phenyl or pyridyl unsubstituted or substituted. Ar1 can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl; R3 can be independently selected from Ar or is hydrogen, hydroxy, NMe2, N-methyl-pyrrole, imidazole, tetrazole, thiazole (a), (b), (c), or (d), wherein Ar2 is phenyl or pyridyl. The instant compounds antagonize the bombesin receptors in mammals and are therefore effective in treating and/or preventing depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders, inflammatory bowel disease, sleep disorders, and memory impairment.

  该刻即发明的化合物是Formula I的新型化合物或其药用可接受的盐，其中Ar是未取代或取代的苯基或吡啶基。Ar1可以独立地从Ar中选择，也可以包括吡啶-N-氧化物、吲哚基、咪唑基和吡啶；R3可以独立地从Ar中选择，或者是氢、羟基、NMe2、N-甲基-吡咯、咪唑、四唑、噻唑(a)、(b)、(c)或(d)，其中Ar2是苯基或吡啶。该刻的化合物对哺乳动物的波美斯因受体具有拮抗作用，因此在治疗和/或预防抑郁症、精神病、季节性情感障碍、癌症、进食障碍、胃肠道疾病、炎症性肠病、睡眠障碍和记忆障碍方面具有有效性。
• [EN] NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE BOMBESINE NON PEPTIDIQUES
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1998007718A1

  公开（公告）日：1998-02-26

  (EN) Compounds of Formula (I) or a pharmaceutically acceptable salt thereof wherein Ar is phenyl or pyridyl unsubstituted or substituted. Ar1 can be independently selected from Ar and can also include pyridyl-N-oxide, indolyl, imidazole, and pyridyl; R3 can be independently selected from Ar or is hydrogen, hydroxy, NMe2, N-methyl-pyrrole, imidazole, tetrazole, thiazole (a), (b), (c) or (d), wherein Ar2 is phenyl or pyridyl. The compounds of the instant invention are novel compounds which antagonize the bombesin receptors in mammals and are therefore effective in treating and/or preventing depression, psychoses, seasonal affective disorders, cancer, feeding disorders, gastrointestinal disorders, inflammatory bowel disease, sleep disorders, and memory impairment.(FR) Cette invention se rapporte à des composés représentés par la formule (I) ou à un sel de ces composés acceptable sur le plan pharmaceutique. Dans cette formule, Ar représente phényle ou pyridyle substitué ou insubstitué; Ar1 peut être sélectionné indépendamment dans Ar et peut également contenir pyridyl-N-oxyde, indolyle, imidazole et pyridyle; R3 peut être sélectionné indépendamment dans Ar ou représente hydrogène, hydroxy, NMe2, N-méthyle-pyrrole, imidazole, tétrazole, thiazole (a), (b), (c) ou (d), où Ar2 représente phényle ou pyridyle. Les composés faisant l'objet de cette invention sont des nouveaux composés qui ont un effet antagoniste sur les récepteurs de bombésine chez les mammifères et qui sont par conséquent efficaces pour traiter et/ou prévenir la dépression, les psychoses, les troubles affectifs saisonniers, le cancer, les troubles de l'alimentation, les troubles gastro-intestinaux, les maladies intestinales inflammatoires, les troubles du sommeil et les déficiences de la mémoire.

  化合物的化学式为(I)，或其药学上可接受的盐，其中Ar是未取代或取代的苯基或吡啶基。Ar1可以独立于Ar选择，也可以包括吡啶-N-氧化物、吲哚基、咪唑和吡啶；R3可以独立于Ar选择，也可以是氢、羟基、NMe2、N-甲基吡咯、咪唑、四氮唑、噻唑(a)、(b)、(c)或(d)，其中Ar2是苯基或吡啶基。本发明的化合物是新的化合物，能拮抗哺乳动物中的瘤胃素受体，因此有效地治疗和/或预防抑郁症、精神病、季节性情感障碍、癌症、进食障碍、胃肠障碍、炎症性肠病、睡眠障碍和记忆障碍。
• Treatment of sexual dysfunction
  申请人：——

  公开号：US20020169101A1

  公开（公告）日：2002-11-14

  Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

  Bombesin受体拮抗剂已被发现在男性和女性的性功能障碍治疗中非常有用。它们可以是选择性BB1拮抗剂或混合BB1 / BB2拮抗剂。揭示了与一系列其他活性化合物的Bombesin受体拮抗剂的组合，例如PDE5抑制剂，NEP抑制剂和lasofoxifene。
• Bombesin receptor antagonists
  申请人：——

  公开号：US20040110768A1

  公开（公告）日：2004-06-10

  Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: 1 wherein j, k, l, m, n, q, r, Ar, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X are as defined in the description. The compounds of the invention have an affinity for the BB 1 receptor and some of them also have affinity for the BB 2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.

  提供了化合物(I)或其药学上可接受的盐，其是Bombesin受体拮抗剂：1其中j、k、l、m、n、q、r、Ar、Ar1、R1、R2、R3、R4、R5、R6和X如说明书中所定义的。本发明的化合物具有对BB1受体的亲和力，其中一些化合物还具有对BB2受体的亲和力。因此，它们可能对男性和女性的性功能障碍的诊断、预防或治疗有用。它们还可用于焦虑和恐慌障碍、社交恐惧症、抑郁症、精神病、睡眠障碍、记忆障碍、肺动脉高压、肺修复和肺发育障碍、包括前列腺癌和胰腺癌在内的癌症、肝卟啉症、胃肠分泌紊乱、包括结肠炎、克罗恩病和炎症性肠病在内的胃肠疾病、呕吐、厌食、疼痛、季节性情感障碍、进食障碍或瘙痒的诊断、预防或治疗中使用。